Braftovi 75 MG capsule 90S
Ended Awarded Last action
- Contract number
- SPE2DR26F1AM6
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $22,750
Award facts
- Contract value 100% obligated
- $22,749.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order from the Defense Logistics Agency (DLA) on January 22, 2026, for Braftovi 75 mg capsules (90-count units) with a ceiling value of $22,749.60. This firm fixed-price, non-set-aside contract is scheduled for completion by February 12, 2026, and will be performed at the awardee's Conshohocken facility. The delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, a comprehensive global pharmaceutical support vehicle valued at up to $999,999,999.00 through December 2031 that enables the supply of a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide.
This award reflects AmerisourceBergen's established role as a critical vendor within the federal medical supply chain, particularly for Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. Braftovi (encorafenib) is an oncology medication used in the treatment of certain melanomas and colorectal cancers, consistent with the company's demonstrated capability to deliver specialized pharmaceutical products across multiple therapeutic domains. The non-set-aside, competitively awarded status of this delivery order further validates the contractor's ability to meet federal procurement requirements in open competition.
Quick answers
Who was awarded contract SPE2DR26F1AM6?
SPE2DR26F1AM6 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 22, 2026.
How much is contract SPE2DR26F1AM6 worth?
The government has obligated $22,750 on SPE2DR26F1AM6.
Is contract SPE2DR26F1AM6 an order under another contract?
Yes. SPE2DR26F1AM6 is a delivery order under SPE2DR25D1205, an indefinite delivery contract.
Was contract SPE2DR26F1AM6 competed?
The extent of competition for SPE2DR26F1AM6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award